secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089235
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024
-------------------------------------------------------------------

- Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.
- R&D expenses $48.7M, SG&A $29.1M; FY2024 opex guidance $355-375M with sufficient capital through 2026.
- Revumenib NDA for R/R KMT2Ar leukemia PDUFA extended to Dec 26, 2024; AUGMENT-101 mNPM1 AML data expected 4Q24.
- Axatilimab BLA for chronic GVHD under Priority Review with PDUFA date Aug 28, 2024.
- Appointed Dr. Aleksandra Rizo to Board of Directors in May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024089235/0000950170-24-089235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024089235/sndx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer